<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02272894</url>
  </required_header>
  <id_info>
    <org_study_id>E201419A</org_study_id>
    <nct_id>NCT02272894</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Superior Mesenteric Vein (14V) Lymphadenectomy for Distal Advanced Gastric Cancer</brief_title>
  <official_title>Randomized Controlled Trial to Evaluate Mesenteric Vein (14V) Lymphadenectomy for Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qinghai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wulumuqi General Hospital of Lanzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is going to evaluate the advantage of D2 radical gastrectomy plus 14v lymph node
      dissection in 3-year survival rates of advanced gastric cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radical surgery is still the only possible way to cure gastric cancer. In Japan, South Korea
      and other countries, due to the popularity of screening and Improved surgical procedures,
      there has been great improvement in overall survival. Standard D2 Gastrectomy has been the
      standard operation for advanced gastric cancer. However, there is no unanimous consensus
      whether Standard D2 Gastrectomy plus 14v lymph node dissection is needed.Till now, it is
      difficult to stage the 14V lymph node as regional lymph nodes metastasis or distant
      metastasis. And it is urgent to explore the necessity of 14v lymph node dissection in
      advanced gastric cancer.So a prospective randomized controlled study will to carry out to
      evaluate the effects of D2 radical gastrectomy plus 14v lymph node dissection compared with
      D2 radical gastrectomy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival (OS) was defined as the length of time from the date of randomization to the date of death of various reasons.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Disease free survival (DFS) was defined as the length of time from the date of randomization to the date of first documentation of relapse of gastric cancer or any other type of cancer or death.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>D2 Radical Gastrectomy Adding Dissection of the Superior Mesenteric Vein Lymph Node</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>D2 Radical Gastrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dissection of the Superior Mesenteric Vein Lymph Node</intervention_name>
    <description>14v lymph node dissection</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Distal Advanced Gastric Cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Curative D2 or D2+ operation had been performed;

          -  Physical condition and organ function allows to tolerable abdominal surgery;

          -  Willing and able to comply with the program during the study period;

          -  Aged 18 to 70 years, preoperative gastric cancer patients with pathologically
             confirmed;

          -  With more than a 6-month life expectancy;

          -  No other serious concomitant diseases;

          -  No adjuvant chemotherapy before recurrence;

          -  Karnofsky performance status scale â‰¥ 60;

          -  All patients accept 6 cycles XELOX chemotherapy regimen

        Exclusion Criteria:

          -  Pregnancy or breast feeding;

          -  Women of childbearing age do not take contraceptive measures;

          -  Organ transplantation patients need immunosuppressive therapy;

          -  Five years after the trial begin,other malignant tumor occur;

          -  While using other experimental drug or other clinical trials are being;

          -  Can not take oral medications;

          -  Mentally disordered;

          -  Severe recurrent infections were not controlled or with other serious concomitant
             diseases;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han Liang, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Han Liang, Master</last_name>
    <phone>086-022-23340123</phone>
    <phone_ext>1061</phone_ext>
    <email>tjlianghan@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Han, Master</last_name>
      <phone>086-022-23340123</phone>
      <phone_ext>1061</phone_ext>
      <email>tjlianghan@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2014</study_first_submitted>
  <study_first_submitted_qc>October 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2014</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>D2 Lymphadenectomy</keyword>
  <keyword>Superior Mesenteric Vein Lymph Node</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

